Previous 10 | Next 10 |
By a 19-9 vote, the Prescription Drug Pricing Reduction Act has advanced out of the Senate Finance Committee and will go before the full Senate this fall. The bill would cap out-of-pocket costs for medicines at $3,100 per year for Medicare beneficiaries beginning in 2022 and require drug m...
U.S. Senator Jeanne Shaheen (D-NH) has introduced a bipartisan bill , the Insulin Price Reduction Act, that she says will rein in skyrocketing costs of insulin while holding pharmacy benefit managers to account for their role in surging prices, adding that the cost of the most popular insul...
Major drug makers are under water nearing the close as skittish investors move the sidelines ahead of President Trump's plan to peg Medicare reimbursement to the lowest ex-U.S. prices from a select group of countries. More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Heal...
Biotechs and biopharma players are modestly in the green after a D.C. district court stopped a Trump administration initiative requiring drug makers to disclose list prices in television advertisements. More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & ...
Oral arguments start today in the U.S. Fifth Circuit Court of Appeals in a case led by Republican Attorneys General to invalidate the Affordable Care Act, known as Obamacare. More news on: The Gabelli Healthcare & Wellness Rx Trust, Tekla World Healthcare Fund, BlackRock Health Scie...
Biopharma and biotech players are mostly in the red (again) ahead of an expected executive order from President Trump aimed at corralling U.S. drug prices. Specifically, the order will contain a "favored nation" clause that will be the basis for Medicare reimbursement, i.e., the reimbursem...
This article was first released to CEF/ETF Income Laboratory subscribers 1 month ago, so data may be out of date. Please check latest data before making investment decisions. Quantitative screens help to rapidly narrow down attractive candidates from the database of 500-plus closed-end...
BlackRock Health Sciences Trust (NYSE: BME ) declares $0.2000/share monthly dividend , in line with previous. Forward yield 6.17% Payable July 31; for shareholders of record July 15; ex-div July 12. See BME Dividend Scorecard, Yield Chart, & Dividend Growth. More news on: B...
Early July is typically one of the two times each calendar year that U.S. drugmakers hike prices. Yesterday, on cue, many appeared to do just that . More news on: GlaxoSmithKline plc, Amneal Pharmaceuticals, Inc., ProShares Ultra Nasdaq Biotechnology ETF, Healthcare stocks news, Stocks on...
It seems, every month for CEFs, there is a new round of distribution cuts at funds. This shouldn't be any surprise as many funds pay out simply unsustainable distributions over the long run. Investors in CEFs know that this is just a part of everyday life, sacrificing distribution growth for t...
News, Short Squeeze, Breakout and More Instantly...
Blackrock Health Sciences Trust Company Name:
BME Stock Symbol:
NYSE Market:
Blackrock Health Sciences Trust Website:
2024-07-10 03:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
The BlackRock closed-end funds (the “Funds”) listed below announced today the results of the Quarterly Measurement Period (as defined below) under their previously announced discount management programs (the “Programs”). Funds with a Trigger Event (as defined below) at...
2024-06-20 05:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...